Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Insulin Pump Market Idea Proposal (TNDM, PODD, MDT)

Insulin Pump Market Idea Proposal (TNDM, PODD, MDT)
 

As the continuous glucose monitoring market continues to innovate, integrate, and grow, are insulin pump makers Tandem, Insulet, and Medtronic poised to follow?

Report Available: September 3, 2020

 

Blueshift’s initial research found the continues glucose monitoring (CGM) market experiencing increasing demand from both Type 1 and Type 2 diabetics. The CGM space has also experienced the approval and introduction of next-gen products and new and expanded collaborative deals with all of the insulin pump makers. TNDM, PODD and MDT have all signed agreements with CGM producers to collaborate and integrate their products to encourage both Type 1 & Type 2 insulin users to consider CGM and automatic pumping. The insulin pump market has, for the most part, been limited to Type 1 diabetics requiring frequent insulin shots per day. The extent to which the proliferation of CGM use among both Type 1 and Type 2 diabetics can serve as a driver to increase pump adoption is unknown.

 

Observations

  1. The CGM market has experienced a surge in demand during COVID-19, and GlobalData expects CGM market growth to reach mid-double digits in 2020. The three major CGM players, DXCM, ABT and MDT, all reported high demand. DXCM logged 44% YY growth for Q1 and 34% in Q2, while ABT grew 62.5% YY in Q1 and 60% in Q2. MDT reported high demand for its diabetic supplies and consumables, but its diabetic division is still experiencing declines.
  2. The insulin pump market also experienced continued growth while navigating the coronavirus. Fortune Business Insights recently released a report that predicts a 9.4% increase in the insulin pump market by 2027. TNDM reported worldwide sales of its pumps up 17% YY and U.S. shipments up 15%YY in Q2. PODD experienced a 25% YY revenue increase in the quarter, and MDT, despite losing U.S. market share as it awaits FDA approval of its next-gen pump, saw revenue rise 2.2% on the strength of international sales of it 670 Hybris closed-loop system.
  3. On June 12, ABT received FDA approval for its FreeStyle Libre 2 Flash Glucose Monitoring System. ABT had been awaiting an FDA determination since April 2019. The Libre received iCGM designation with the exception that it cannot be used with automated insulin dosing (AID) systems due to inaccurate sensor readings when a patient is taking vitamin C supplements. ABT still plans to pursue future integration with systems from PODD, TNDM, MDT, and Bigfoot, but it is unclear if it will try for approval with the Libre 2 or wait until a future Libre is tested and approved.
  4. Automated insulin delivery systems market leaders TNDM and PODD, along with start-up Bigfoot Biomedical, have all partnered with ABT and DXCM to integrate their pumps with their CGM systems. These collaborations will provide more patient choice for which CGM system and pump they want to use, increasing the competitive environment. It is unclear, however, how the FDA’s restrictions on the Libre 2 regarding integration with insulin pumps will affect these agreements and the diabetes community in general.
  5. Blueshift’s March 26 report noted that DXCM is seen as the leader in the CGM market and, as insurance coverage increases and pump manufacturers continue to integrate its CGMs with their devices, DXCM sales will continue to increase. It also said that a TNDM pump combined with DXCM’s CGM is the insulin pump of choice, especially for younger diabetics. TNDM’s t:slim X2 with Control-IQ Technology is expected to be the primary beneficiary of MDT’s anticipated patient loss from the Class I recall of its MiniMed insulin pumps. Sources praised TNDM and its pumps as excellent, with the best trial results. Increased sales of the t:slim X2 are expected until the next technology breakthrough comes. Blueshift’s 23, 2019, report update revealed DXCM’s and TNDM’s growth trends would not be disrupted over the next six to 12 months. Sources cited ease of use, superior performance and reliability, solid insurance reimbursement, and strong research and development with exciting product pipelines as factors that are contributing to each company’s success. These findings are in line with Blueshift’s June 19, 2019, TNDM report and April 25, 2019, DXCM report.

 

Will the recent CGM innovation and expanded use of CGM systems result is increased use of insulin pumps over the next 18 to 24 months? Are the current insulin pumps ready for prime time in the way CGM is being touted and adopted? What percentage of the Type 1 diabetes market will be pumpers in 18 to 24 months? Will Type 2 insulin users consider using pumps? How many? Which insulin pump company stands to gain or lose the most share?  To answer these and other questions, Blueshift will gather data and issue a market research report from independent sources in the following areas: Endocrinologists, Nurse educators, Diabetes centers, Diabetes sales channel, Competitors, and Industry specialists.  

 

Companies: Abbott Laboratories (ABT), Dexcom Inc. (DXCM), Insulet Corporation (PODD), Medtronic plc (MDT), Senseonics Holdings Inc. (SENS), Tandem Diabetes Care Inc. (TNDM)

 

Research Begins: August 17, 2020

 

To see other ideas Blueshift Research is currently working on, please click here.

 

Blueshift Research’s sister company, Intro-act, has launched the Intro-act Scorecard, the C-suite’s standard, ongoing measure of corporate investor engagement.

 

The Scorecard optimizes the ROI on corporate access by measuring: Concentration, Directionality, Breadth, Impact, Depth, and Duration

 

See the sample Scorecard. Watch the Scorecard video.